Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.</li><li>The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.</li><li>DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.</li></ul>

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year.The U.S. market drove much of this growth, achieving a 15% increase in revenue, fueled by robust demand and broader access to their continuous glucose monitoring (CGM) systems.DexCom's strategic focus on expanding their prescriber base and enhancing commercial reach has begun to manifest in increased customer acquisition, particularly in the type 2 diabetes sector, where their coverage has expanded significantly.

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move?

<ul><li>DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's guidance and expectations.</li><li>The company achieved an 8% organic revenue growth in the fourth quarter year-over-year, with full-year organic growth at 12%.</li><li>An increase in the customer base by approximately 25% to over 2.8 million globally was a critical driver of this growth.</li></ul>

DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's guidance and expectations.The company achieved an 8% organic revenue growth in the fourth quarter year-over-year, with full-year organic growth at 12%.An increase in the customer base by approximately 25% to over 2.8 million globally was a critical driver of this growth.

Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?

<ul><li>Dexcom, a leader in glucose monitoring technology, recently held its third-quarter 2024 earnings call, presenting both noteworthy achievements and challenges.</li><li>As Dexcom navigates through various market dynamics, their strategic and operational updates offer a mixed outlook that investors should carefully consider.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Dexcom, a leader in glucose monitoring technology, recently held its third-quarter 2024 earnings call, presenting both noteworthy achievements and challenges.As Dexcom navigates through various market dynamics, their strategic and operational updates offer a mixed outlook that investors should carefully consider.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

DexCom Inc.: These Are The 7 Biggest Factors Driving Its Performance In 2025 & Beyond! - Major Drivers

<ul><li>DexCom, Inc. recently reported its second quarter earnings for 2024, presenting a mix of achievements and challenges that provide a nuanced view of the company’s current state and future outlook.</li><li>DexCom, known for its continuous glucose monitoring (CGM) systems, has demonstrated continuous growth in the diabetes management market, yet faced several short-term hurdles that have impacted its performance this quarter.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

DexCom, Inc. recently reported its second quarter earnings for 2024, presenting a mix of achievements and challenges that provide a nuanced view of the company’s current state and future outlook.DexCom, known for its continuous glucose monitoring (CGM) systems, has demonstrated continuous growth in the diabetes management market, yet faced several short-term hurdles that have impacted its performance this quarter.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

DexCom Inc.: A Tale Of Product Innovation and Pipeline Development! - Major Drivers

Research from ACF Equity Research, ACF Equity Research

ACF Equity Research

Research from ACF Equity Research

Accuracy | Clarity | Foresight

ACF was set up to improve the effectiveness of capital markets for smaller and mid-sized companies. The majority of jobs are created by smaller companies not global companies. If we can help improve companies use of capital markets more projects will be completed, more jobs created, more global GDP grown, which in turn helps create more resources for education, leading to equality and opportunity for those who are still oppressed by ignorance and poverty.

ACF Equity Research is an independent research house specialising in the highest specification independent equity research for corporate clients.

We deliver premium independent corporate sponsored equity research characterised by its accuracy, clarity and foresight based upon a fundamental valuation approach.

Our independent research is designed to educate our professional investor readers about your company, with an emphasis on clear and accurate explanations. Our mission is to improve company’s liquidity through credible equity research services, excellent international distribution and reliable access for investment managers.

We believe in the importance and value of clarity, the careful articulation of technical ideas, concepts and solutions.

Our team of analysts are independently minded individuals who believe in thoroughness, technical competence and clear punchy communications.

Thematic (Sector/Industry)

<ul>
<li>We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM).</li>
<li>We provide an investment case analysis and a selection of merged metrics prior to any synergies.</li>
<li>The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurodegenerative diseases (NDDs); and a clinical-stage Dual Orexin Receptor Agonist (DOXA) platform targets NDD therapies and metabolic disorders including ALS and sleep-wake disorders.</li>
</ul>


We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM).
We provide an investment case analysis and a selection of merged metrics prior to any synergies.
The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurodegenerative diseases (NDDs); and a clinical-stage Dual Orexin Receptor Agonist (DOXA) platform targets NDD therapies and metabolic disorders including ALS and sleep-wake disorders.


KDST + NLSP Combined Core Investment Case 29052025

United States

DexCom Inc. is a medical device company focused on the design and development of continuous glucose monitoring systems for people with diabetes.  The Company has developed a small implantable device that continuously measures glucose levels in subcutaneous tissue just under the skin, and a small external receiver to which the sensor transmits glucose levels at specified intervals.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Dexcom Inc (DXCM US)

DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move?

DexCom, Inc. reported its first-quarter 2025 earnings, demonstrating a commendable 14% organic revenue growth from the previous year. The U.S....

Baptista Research

Dexcom Inc.: Will Sensor Tech Advancements Solidify Its Lead In Continuous Glucose Monitoring?

DexCom Inc.'s latest earnings for the fourth quarter of 2024 reports a period of strategic growth and investment, aligning with the company's...

Baptista Research

DexCom Inc.: These Are The 7 Biggest Factors Driving Its Performance In 2025 & Beyond! - Major Drivers

Dexcom, a leader in glucose monitoring technology, recently held its third-quarter 2024 earnings call, presenting both noteworthy achievements and...

Baptista Research

DexCom Inc.: A Tale Of Product Innovation and Pipeline Development! - Major Drivers

DexCom, Inc. recently reported its second quarter earnings for 2024, presenting a mix of achievements and challenges that provide a nuanced view...

Baptista Research

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of...

ACF Equity Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)